Halozyme Therapeutics Inc stock is traded at $95.80, with a volume of 1,609,368. It is down -0.18% in the last 24 hours and down -21.80% over the past month. Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. ENHANZE drug delivery technology was introduced with the proprietary enzyme rHuPH20, to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid SC delivery and reduced treatment burden. The company's operations are based in the United States, with minimal long-lived assets located internationally.
Previous Close:
$95.97
Open:
$95.29
24h Volume:
1,609,368
Relative Volume:
0.61
Market Cap:
$10.92B
Revenue:
$1.51B
Net Income/Loss:
$348.84M
P/E Ratio:
34.45
EPS:
$2.78
Net Cash Flow:
$667.65M
1W Performance:
-4.84%
1M Performance:
-21.80%
6M Performance:
+39.39%
1Y Performance:
+36.37%
1-Day Range:
$95.01$97.96
1-Week Range:
$94.93$101.75
52-Week Range:
$61.23$134.00
Halozyme Therapeutics Inc Stock (HALO) Company Profile
Name
Halozyme Therapeutics IncSector
HealthcareIndustry
BiotechnologyPhone
(858) 794-8889Address
12390 EL CAMINO REAL, SAN DIEGO, CA, USAMarket Cap
Revenue
Net Income
Cash Flow
EPS